Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/MDMA/Older Adults

MDMA for Older Adults

9 papers and 0 clinical trials exploring mdma as a treatment for older adults.

Compoundempathogen

MDMA

MDMA is a synthetic empathogen that enhances monoamine release, producing prosocial and anxiolytic effects without frank hallucinosis. Two Phase III trials demonstrated significant PTSD symptom reductions, though FDA review raised concerns about blinding, durability, and safety characterisation.

Full MDMA profile
IndicationApproximately 300 million adults worldwide struggle with depression, many of whom are older adults.

Older Adults

Psychedelic research involving older adults is gaining traction, highlighting the potential therapeutic benefits of compounds such as psilocybin and MDMA. Recent studies suggest promising safety profiles and efficacy, paving the way for future clinical applications in this demographic.

Full Older Adults profile

Academic Research

9 papers
Open Accessindividual

Age moderates the relationship between psychedelics use and mental health in naturalistic settings

This cross-sectional survey (n=1,088) found that age significantly moderates the relationship between lifetime psychedelic use and mental health, with classic psychedelics such as psilocybin being associated with lower depression and anxiety in younger adults, but these benefits diminish with age and even reverse for anxiety in older participants.

Published
March 10, 2026
Journal
Research Square
Authors
Gregorio, G. D., Basset, S., Manmohan, H., Nixon, W. C., Pogaku, A., Zhou, J., Sanderson, D. J., Lengieza, M. L., Bocchio, M.
Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
February 18, 2026
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.
Open Accessindividual

Naturalistic psychedelic use and changes in depressive symptoms

This longitudinal observational study (n=12,345) of U.S. residents found that naturalistic psychedelic use (n=505, 4.1% of participants) was associated with modest increases in depressive symptoms, particularly when occurring in 'risk contexts' characterised by negative mindset and lack of psychological support, with challenging psychedelic experiences mediating this relationship and suggesting that unsupervised psychedelic use may not be generally therapeutic and could worsen depression under certain circumstances.

Published
December 1, 2025
Journal
Journal of Affective Disorders
Authors
Simonsson, O., Hendricks, P. S., Swords, C. M., Osika, W., Goldberg, S. B.
Open Accessmeta

MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations

This article (2023) advocates for MDMA-assisted psychotherapy (MDMA-AT) in treating adolescent PTSD, highlighting potential benefits such as reduced avoidance and enhanced therapeutic alliance. It proposes adaptations including stronger motivation reinforcement, additional emotion management techniques, and family involvement, and calls for clinical trials to assess safety and effectiveness.

Published
July 2, 2023
Journal
European Child and Adolescent Psychiatry
Authors
Kangaslampi, S., Zijlmans, J.
Paywallindividual

Past-Year Hallucinogen Use in Relation to Psychological Distress, Depression, and Suicidality among US Adults

This study used a sample from the U.S. National Survey on Drug Use and Health (n=241,675) to assess if past-year psychedelic use is associated with reporting past-year serious psychological distress (SPD), major depressive episode (MDE), and suicidality. LSD was associated with an increased likelihood of MDE and suicidal thinking. MDMA use was associated with a decreased likelihood of SPD and suicidal thinking.

Published
September 1, 2022
Journal
Addictive Behaviors
Authors
Yang, K. H., Han, B. J., Palamar, J. J.
Paywallindividual

Micro-dosing psychedelics as a plausible adjunct to psychosexual and couple’s therapy: a qualitative insight

This interview study (n=4 couples) explored the MDMA micro-dosing sexual experiences of four partnered men and women. Thematic analysis identified three key narratives: increased sexual self-efficacy; sexual exploration; and heightened relationship satisfaction. The use of microdosing MDMA had a positive effect on sexual and physical well-being by reducing stress and performance-related anxiety. Whilst higher doses of MDMA hindered sexual functioning this did not negatively impact the emotional and sensory experiences.

Published
February 28, 2022
Journal
Sexual and Relationship Therapy
Authors
Jacobs, L., Banbury, S., Lusher, J.

Clinical Trials

0 trials

No clinical trials have been tagged with both MDMA and Older Adults yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all MDMA papers Search all Older Adults trials Full MDMA profile Full Older Adults profile